Kymera Therapeutics Inc. (KYMR)

Business: Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.

IPO Date: 21-Aug-2020

Co-Founder & Chairman: Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D.

Co-Founder, Pres, CEO & Director: Dr. Nello Mainolfi M.D., Ph.D.

Listing: NASDAQ: KYMR

Country: United States

Headquarters: Watertown, MA

Website: https://www.kymeratx.com

Market cap: $1,049.48 Mln

Revenue (TTM): $63.75 Mln

Earnings (TTM): $-123.83 Mln

Cash: $420.81 Mln

Total Debt: $17.47 Mln

Insider's Holding: 8.29%

Liquidity: Low

52 Week range: $13.15 - 69.12

Shares outstanding: 51,724,200